ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
11.18
-0.14 (-1.24%)
Dec 20, 2024, 4:00 PM EST - Market closed
ARS Pharmaceuticals Analyst Ratings
Total Analysts
4
Consensus Rating
Strong Buy
Price Target
$24.00
Upside
+114.67%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +168.34% | Oct 8, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $21 → $25 | Buy | Maintains | $21 → $25 | +123.61% | Sep 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +168.34% | Sep 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +168.34% | Sep 9, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $30 | Buy | Initiates | $30 | +168.34% | Aug 20, 2024 |
| Raymond James | Raymond James | Buy → Strong Buy Upgrades $18 → $22 | Buy → Strong Buy | Upgrades | $18 → $22 | +96.78% | Aug 13, 2024 |
| Raymond James | Raymond James | Buy Initiates $18 | Buy | Initiates | $18 | +61.00% | Jul 25, 2024 |
| Wedbush | Wedbush | Buy Reiterates $19 | Buy | Reiterates | $19 | +69.95% | Mar 11, 2024 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $6 → $18 | Hold → Buy | Upgrades | $6 → $18 | +61.00% | Mar 5, 2024 |
| Wedbush | Wedbush | Buy Maintains $5 → $13 | Buy | Maintains | $5 → $13 | +16.28% | Nov 13, 2023 |
| Wedbush | Wedbush | Buy Maintains $15 → $5 | Buy | Maintains | $15 → $5 | -55.28% | Sep 21, 2023 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Sep 20, 2023 |
| Wedbush | Wedbush | Buy Reiterates $15 | Buy | Reiterates | $15 | +34.17% | Aug 14, 2023 |
| Wedbush | Wedbush | Buy Maintains $17 → $15 | Buy | Maintains | $17 → $15 | +34.17% | Jun 21, 2023 |
| Wedbush | Wedbush | Buy Reiterates $17 | Buy | Reiterates | $17 | +52.06% | May 18, 2023 |
| Wedbush | Wedbush | Buy Reiterates $17 | Buy | Reiterates | $17 | +52.06% | May 12, 2023 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.